Predicting progression of HIV disease: usefulness of acid-dissociated p24 antigen. 1994

L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
Service de Bacterio-Virologie, Hôpital Saint-Antoine, Paris, France.

To ascertain whether immune complex dissociation (ICD) improves the value of p24 antigen as a prognostic marker for progression of HIV infection, 53 patients were followed over a 3-year period, including at least one visit per year. All had CD4+ counts at entry > 400/mm3; progressors (n = 18) were defined as having CD4+ counts < 200/mm3 and nonprogressors (n = 35) as having CD4+ counts still > 400/mm3 at the end of follow-up. Serum specimens were collected at each annual visit and assayed for p24 antigen with and without ICD treatment. At entry, the percentage of progressors positive for ICD p24 antigen was significantly higher than the percentage of positive nonprogressors (39% versus 3%, p < 0.01). The sensitivity of p24 antigen over all visits in terms of predicting the progression increased from 61% before ICD to 83% after. The specificity of p24 antigen in terms of predicting progression decreased from 97% before ICD to 89% after. The relative risk of progression in individuals positive for p24 antigen was 6.7 before ICD and increased after ICD to 12.7. When evaluating the respective prognostic value of the p24 antigen and of the ICD p24 antigen, only ICD p24 was significant (RR 10.2, 95% CI 2.2-46.9). ICD p24 antigen appears to be a marker of progression that may be detected earlier than p24 antigen without ICD.

UI MeSH Term Description Entries
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006851 Hydrochloric Acid A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE. Hydrogen Chloride,Muriatic Acid,Acid, Hydrochloric,Acid, Muriatic,Chloride, Hydrogen
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000936 Antigen-Antibody Complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES. Immune Complex,Antigen-Antibody Complexes,Immune Complexes,Antigen Antibody Complex,Antigen Antibody Complexes,Complex, Antigen-Antibody,Complex, Immune,Complexes, Antigen-Antibody,Complexes, Immune

Related Publications

L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
November 1993, AIDS (London, England),
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
December 1990, The American journal of medicine,
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
August 1994, Journal of acquired immune deficiency syndromes,
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
December 1997, AIDS patient care and STDs,
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
April 1992, Lancet (London, England),
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
February 1992, Lancet (London, England),
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
September 1992, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
October 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
September 1995, Journal of medical virology,
L Morand-Joubert, and D Costagliola, and H Bludau, and J C Petit, and J J Lefrère
January 2016, Indian journal of medical microbiology,
Copied contents to your clipboard!